Total supply chain services (TSCS)
Total supply chain services (TSCS)
Total supply chain services (TSCS) refer to the organic, integrated utilization of the various functions possessed by the Alfresa Group to enable the establishment of a seamless supply chain and the Group’s unified provision of services in areas extending from the introduction, development, and manufacture of pharmaceuticals and other products through to their distribution, sales, post-marketing surveillance and last-mile operations.
TSCS eliminates drug lag-drug loss, situations in which innovative pharmaceutical products developed by emerging overseas biopharmaceutical companies experience delays or cannot be introduced and utilized in Japan, thereby improving patients’ access to pharmaceutical products. It also contributes to improvement in self-sufficiency rate of pharmaceutical products and stable supply by addressing various modalities (new treatments and dosage forms).
TSCS plays a central role in the business strategy of the Medium- to Long-Term Vision of the Alfresa Group, which aims to create social value by extending healthy life expectancies, contributing to community healthcare, and fostering healthcare innovation.
Functions of TSCS
TSCS covers the entire supply chain of pharmaceutical products with the companies and businesses under the Alfresa Group such as Ark Medical Solutions Inc. with more than 30 years of experience as a CRO*1, Alfresa Pharma Corporation, which has been operating a full-fledged contract-based manufacturing business since 2009, Cell Resources Corporation, which is building a manufacturing framework of global standards of quality and reproducibility in the regenerative medicine field, and the ethical pharmaceuticals wholesaling business with a distribution network boasting the largest net sales. TSCS also collaborates with alliance partners to ensure comprehensive supply chain coverage.
We will offer the most suitable services addressing the needs of pharmaceutical companies in Japan and abroad that aim to optimize their new investments in items such as manufacturing equipment and focus on drug discovery.
- CRO (contract research organization): A specialized organization that supports the series of operations related to clinical trials carried out by pharmaceutical companies and research institutions.
Values brought about by TSCS
Social value:
TSCS contributes to the elimination of drug lag-drug loss and solving the issue of low self-sufficiency rate caused by dependence on foreign countries for ethical pharmaceuticals and their raw materials as well as to ensuring stable supply of newly developed pharmaceutical products through various modalities.
Corporate value:
By evolving and expanding TSCS, we aim to establish a competitive edge and sustainably increase our corporate value through the acquisition of limited distribution products, expansion of CDMO*2 business, and the stable management of supply chain that handles various modalities, including regenerative medicine-related products, which are particularly difficult to manage.
- CDMO (Contract development and manufacturing organization): An organization that provides contract services ranging from development of manufacturing processes for pharmaceuticals to investigational and commercial manufacturing.
Expansion into regenerative medicine and biosimilars
Strengthening the domestic pharmaceutical production structure has been an issue from the perspective of economic security that ensures stable supply of drugs to patients in the event of an emergency. In particular, Japan currently has almost no production facilities for biosimilars*3 or regenerative medicine products.
In addition to ethical pharmaceuticals, Alfresa Group is building TSCS also in the field of biosimilars and regenerative medicine drugs.
- Biosimilars: Equivalent products of similar quality of biopharmaceuticals (structurally complex pharmaceuticals, whose active ingredients include protein, generated by living organisms through genetic modification or cell culturing, that are expected to be effective on diseases which are hard to treat using conventional synthetic pharmaceuticals) already approved and sold in Japan that are sold by a different pharmaceutical company after the expiration of the original product’s patent period and reexamination period.
PATH Solution service to comprehensively support emerging overseas biopharmaceutical companies seeking to enter the Japanese market
We are offering the PATH Solution, a highly flexible service supporting emerging overseas biopharmaceutical companies seeking to enter the Japanese market that allows them to put together various required services depending on the needs arising in the process from initial market entry assessment to regulatory approval as well as the post-launch distribution.
Click the image below for details.
